The Molluscum Contagiosum Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Molluscum Contagiosum Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Molluscum Contagiosum Market.

Some of the key takeaways from the Molluscum Contagiosum Pipeline Report:

• Companies across the globe are diligently working toward developing novel Molluscum Contagiosum treatment therapies with a considerable amount of success over the years. 
• Molluscum Contagiosum companies working in the treatment market are  Competition Deep Dive, Novan, Inc., Veloce Biopharma, Gurina Foundation, Azafaros, Polaryx Therapeutics, Abbott, Medtronic, Merck & Co., Inc., Pfizer Inc., Siemens Healthcare GmbH, Novartis AG, and others, are developing therapies for the Molluscum Contagiosum treatment 

• Emerging Molluscum Contagiosum therapies in the different phases of clinical trials are- VP-102, SB206, VB4-245, SB206, Picato, and others are expected to have a significant impact on the Molluscum Contagiosum market in the coming years.   
• In January 2024, Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has announced today that the U.S. Food and Drug Administration (FDA) has given approval for ZELSUVMI™ (berdazimer topical gel, 10.3%) for managing molluscum contagiosum (molluscum) in adults and pediatric patients aged one year and older. This marks the FDA’s approval of ZELSUVMI as the first innovative medication for treating molluscum infections.

Molluscum Contagiosum Overview

Molluscum contagiosum is a viral skin infection caused by the molluscum contagiosum virus (MCV), which belongs to the poxvirus family. It is characterized by small, raised, flesh-colored bumps or lesions on the skin.

Get a Free Sample PDF Report to know more about Molluscum Contagiosum Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/molluscum-contagiosum-pipeline-insight

Emerging Molluscum Contagiosum Drugs Under Different Phases of Clinical Development Include:

• VP-102: Verrica Pharma
• SB206: Novan/Ligand Pharma
• Picato: LEO Pharma
• SB 206 (Berdazimer Sodium): Novan Inc
• VBP-245 (Povidone Iodine Topical): Veloce Biopharma

Molluscum Contagiosum Route of Administration

Molluscum Contagiosum pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
•  

Molluscum Contagiosum Molecule Type

Molluscum Contagiosum Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Molluscum Contagiosum Pipeline Therapeutics Assessment

• Molluscum Contagiosum Assessment by Product Type
• Molluscum Contagiosum By Stage and Product Type
• Molluscum Contagiosum Assessment by Route of Administration
• Molluscum Contagiosum By Stage and Route of Administration
• Molluscum Contagiosum Assessment by Molecule Type
• Molluscum Contagiosum by Stage and Molecule Type

DelveInsight’s Molluscum Contagiosum Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Molluscum Contagiosum product details are provided in the report. Download the Molluscum Contagiosum pipeline report to learn more about the emerging Molluscum Contagiosum therapies

Some of the key companies in the Molluscum Contagiosum Therapeutics Market include:

Key companies developing therapies for Molluscum Contagiosum are – Deep Dive, Novan, Inc., Veloce Biopharma, Gurina Foundation, Azafaros, Pfizer Inc., Siemens Healthcare GmbH, Novartis AG, Polaryx Therapeutics, Abbott Medtronic, Merck & Co., Inc., and others.

Molluscum Contagiosum Pipeline Analysis:

The Molluscum Contagiosum pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Molluscum Contagiosum with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Molluscum Contagiosum Treatment.
• Molluscum Contagiosum key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Molluscum Contagiosum Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Molluscum Contagiosum market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Molluscum Contagiosum drugs and therapies

Molluscum Contagiosum Pipeline Market Drivers

• The expected launch of newly approved therapies, VP-102 and SB206, is likely to spur market growth in the near future. These might lead to a revolutionary class of topical therapies (drug-device combo) that can offer a safe and effective alternative to aspecific treatments offered to MC patients
• Increasing prevalence of the disease
• Increasing demand for therapy with ease of administration and a longer time of action is likely to boost market uptake of new therapies.
• Molluscum contagiosum is a viral infection estimated to increase in adults as the number of immune-compromised individuals’ increases.

Molluscum Contagiosum Pipeline Market Barriers

• Introduction of consistent and precise application method containing a controlled formulation with a proven dosing schedule, with testing completed in large populations of patients with molluscum
• Despite a huge disease burden, there is a lack of approved therapies to treat molluscum contagiosum. 
• Refined and advanced clinical trial design.
• Current methods of treatment have significant limitations, including pain, scarring, and unproven efficacy, and many are unsuitable for use in children

Scope of Molluscum Contagiosum Pipeline Drug Insight    

• Coverage: Global
• Key Molluscum Contagiosum Companies: Competition Deep Dive, Novan, Inc., Veloce Biopharma, Gurina Foundation, Azafaros, Polaryx Therapeutics, Abbott, Medtronic, Merck & Co., Inc., Pfizer Inc., Siemens Healthcare GmbH, Novartis AG, and others
• Key Molluscum Contagiosum Therapies: VP-102, SB206, VB4-245, SB206, Picato, and others
• Molluscum Contagiosum Therapeutic Assessment: Molluscum Contagiosum current marketed and Molluscum Contagiosum emerging therapies
• Molluscum Contagiosum Market Dynamics: Molluscum Contagiosum market drivers and Molluscum Contagiosum market barriers 

Request for Sample PDF Report for Molluscum Contagiosum Pipeline Assessment and clinical trials

Table of Contents

1. Molluscum Contagiosum Report Introduction

2. Molluscum Contagiosum Executive Summary

3. Molluscum Contagiosum Overview

4. Molluscum Contagiosum- Analytical Perspective In-depth Commercial Assessment

5. Molluscum Contagiosum Pipeline Therapeutics

6. Molluscum Contagiosum Late Stage Products (Phase II/III)

7. Molluscum Contagiosum Mid Stage Products (Phase II)

8. Molluscum Contagiosum Early Stage Products (Phase I)

9. Molluscum Contagiosum Preclinical Stage Products

10. Molluscum Contagiosum Therapeutics Assessment

11. Molluscum Contagiosum Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Molluscum Contagiosum Key Companies

14. Molluscum Contagiosum Key Products

15. Molluscum Contagiosum Unmet Needs

16 . Molluscum Contagiosum Market Drivers and Barriers

17. Molluscum Contagiosum Future Perspectives and Conclusion

18. Molluscum Contagiosum Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Despite a huge disease burden, there is a lack of approved therapies to treat molluscum contagiosum. 

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/